Alivus Life Sciences Limited (BOM:543322)
India · Delayed Price · Currency is INR 1,056.55
-13.85 (-1.29%)
At close: May 29, 2026
Alivus Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 25,518 | 23,869 | 22,832 | 21,612 | 21,232 | |
Revenue Growth (YoY) | 6.91% | 4.54% | 5.64% | 1.79% | 12.63% |
Cost of Revenue | 10,666 | 11,308 | 10,399 | 10,469 | 10,677 |
Gross Profit | 14,853 | 12,561 | 12,433 | 11,144 | 10,555 |
Selling, General & Admin | 2,725 | 2,705 | 2,701 | 1,896 | 1,744 |
Other Operating Expenses | 4,155 | 3,012 | 2,976 | 2,819 | 2,643 |
Operating Expenses | 7,633 | 6,323 | 6,212 | 5,136 | 4,766 |
Operating Income | 7,219 | 6,238 | 6,221 | 6,008 | 5,789 |
Interest Expense | -53.72 | -24.14 | -15.46 | -5.47 | -279.62 |
Interest & Investment Income | - | 200.13 | 120.21 | 157.66 | 67.81 |
Currency Exchange Gain (Loss) | - | 35.79 | -6.37 | 130.23 | 76.04 |
Other Non Operating Income (Expenses) | 604.11 | 33.63 | 0.21 | 1.68 | 3.19 |
EBT Excluding Unusual Items | 7,770 | 6,483 | 6,320 | 6,292 | 5,657 |
Gain (Loss) on Sale of Investments | - | 76.15 | - | - | - |
Gain (Loss) on Sale of Assets | - | -18.21 | -7.04 | -5.58 | -7.43 |
Other Unusual Items | -256.57 | - | - | - | - |
Pretax Income | 7,513 | 6,541 | 6,313 | 6,286 | 5,649 |
Income Tax Expense | 1,868 | 1,685 | 1,604 | 1,616 | 1,462 |
Net Income | 5,645 | 4,856 | 4,709 | 4,670 | 4,187 |
Net Income to Common | 5,645 | 4,856 | 4,709 | 4,670 | 4,187 |
Net Income Growth | 16.24% | 3.13% | 0.84% | 11.52% | 19.10% |
Shares Outstanding (Basic) | 123 | 123 | 123 | 123 | 118 |
Shares Outstanding (Diluted) | 123 | 123 | 123 | 123 | 118 |
Shares Change (YoY) | 0.08% | 0.17% | 0.13% | 4.25% | 9.03% |
EPS (Basic) | 45.99 | 39.63 | 38.43 | 38.11 | 35.63 |
EPS (Diluted) | 45.90 | 39.52 | 38.38 | 38.11 | 35.63 |
EPS Growth | 16.14% | 2.97% | 0.71% | 6.97% | 9.26% |
Free Cash Flow | 2,584 | 2,253 | 2,845 | 1,432 | 4,654 |
Free Cash Flow Per Share | 21.01 | 18.34 | 23.19 | 11.69 | 39.60 |
Dividend Per Share | 5.000 | 5.000 | 22.500 | 21.000 | 21.000 |
Dividend Growth | - | -77.78% | 7.14% | - | - |
Gross Margin | 58.20% | 52.63% | 54.45% | 51.56% | 49.71% |
Operating Margin | 28.29% | 26.13% | 27.25% | 27.80% | 27.27% |
Profit Margin | 22.12% | 20.35% | 20.62% | 21.61% | 19.72% |
Free Cash Flow Margin | 10.12% | 9.44% | 12.46% | 6.63% | 21.92% |
EBITDA | 7,973 | 6,788 | 6,691 | 6,394 | 6,141 |
EBITDA Margin | 31.24% | 28.44% | 29.31% | 29.58% | 28.92% |
D&A For EBITDA | 753.57 | 549.75 | 469.84 | 386.04 | 351.91 |
EBIT | 7,219 | 6,238 | 6,221 | 6,008 | 5,789 |
EBIT Margin | 28.29% | 26.13% | 27.25% | 27.80% | 27.27% |
Effective Tax Rate | 24.87% | 25.76% | 25.41% | 25.71% | 25.88% |
Revenue as Reported | 26,122 | 24,215 | 22,953 | 21,902 | 21,379 |
Advertising Expenses | - | 183.7 | 115.47 | 90.07 | 54.96 |